Zacks Research Issues Negative Forecast for AbbVie Earnings

AbbVie Inc. (NYSE:ABBV) – Stock analysts at Zacks Research dropped their Q1 2025 earnings per share estimates for AbbVie in a research note issued on Wednesday, November 20th. Zacks Research analyst S. Ganoria now anticipates that the company will post earnings per share of $2.62 for the quarter, down from their previous estimate of $2.67. The consensus estimate for AbbVie’s current full-year earnings is $10.95 per share. Zacks Research also issued estimates for AbbVie’s Q2 2025 earnings at $3.02 EPS, Q3 2025 earnings at $3.10 EPS, Q4 2025 earnings at $3.25 EPS, FY2025 earnings at $11.98 EPS, Q3 2026 earnings at $3.54 EPS and FY2026 earnings at $13.27 EPS.

A number of other brokerages have also weighed in on ABBV. TD Cowen raised their target price on AbbVie from $195.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, October 7th. William Blair raised AbbVie to a “strong-buy” rating in a research note on Friday, August 30th. Sanford C. Bernstein began coverage on shares of AbbVie in a research note on Thursday, October 17th. They issued a “market perform” rating and a $203.00 target price for the company. Piper Sandler lifted their price target on AbbVie from $196.00 to $209.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Finally, Barclays upped their price objective on AbbVie from $200.00 to $212.00 and gave the stock an “overweight” rating in a research report on Monday, October 7th. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $203.50.

AbbVie Price Performance

NYSE:ABBV opened at $176.94 on Friday. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The firm has a market cap of $312.68 billion, a PE ratio of 61.44, a price-to-earnings-growth ratio of 2.03 and a beta of 0.63. The company’s 50-day moving average price is $189.47 and its two-hundred day moving average price is $181.04. AbbVie has a 12 month low of $137.65 and a 12 month high of $207.32.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.92 by $0.08. The business had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.28 billion. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.95 earnings per share.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.71%. The ex-dividend date of this dividend is Wednesday, January 15th. This is a boost from AbbVie’s previous quarterly dividend of $1.55. AbbVie’s payout ratio is currently 215.28%.

Institutional Trading of AbbVie

Several institutional investors have recently added to or reduced their stakes in the company. RPg Family Wealth Advisory LLC acquired a new position in AbbVie in the third quarter valued at about $28,000. Fairway Wealth LLC bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $26,000. Ridgewood Investments LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $27,000. Marquette Asset Management LLC bought a new position in AbbVie in the third quarter valued at approximately $39,000. Finally, Mizuho Securities Co. Ltd. lifted its stake in AbbVie by 100.0% during the third quarter. Mizuho Securities Co. Ltd. now owns 200 shares of the company’s stock worth $39,000 after purchasing an additional 100 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.